Literature DB >> 22179317

ROS-induced ATF3 causes susceptibility to secondary infections during sepsis-associated immunosuppression.

Wolfram Hoetzenecker1, Bernd Echtenacher, Emmanuella Guenova, Konrad Hoetzenecker, Florian Woelbing, Jürgen Brück, Anna Teske, Nadejda Valtcheva, Kerstin Fuchs, Manfred Kneilling, Ji-Hyeon Park, Kyu-Han Kim, Kyu-Won Kim, Petra Hoffmann, Claus Krenn, Tsonwin Hai, Kamran Ghoreschi, Tilo Biedermann, Martin Röcken.   

Abstract

Sepsis, sepsis-induced hyperinflammation and subsequent sepsis-associated immunosuppression (SAIS) are important causes of death. Here we show in humans that the loss of the major reactive oxygen species (ROS) scavenger, glutathione (GSH), during SAIS directly correlates with an increase in the expression of activating transcription factor 3 (ATF3). In endotoxin-stimulated monocytes, ROS stress strongly superinduced NF-E2-related factor 2 (NRF2)-dependent ATF3. In vivo, this ROS-mediated superinduction of ATF3 protected against endotoxic shock by inhibiting innate cytokines, as Atf3(-/-) mice remained susceptible to endotoxic shock even under conditions of ROS stress. Although it protected against endotoxic shock, this ROS-mediated superinduction of ATF3 caused high susceptibility to bacterial and fungal infections through the suppression of interleukin 6 (IL-6). As a result, Atf3(-/-) mice were protected against bacterial and fungal infections, even under conditions of ROS stress, whereas Atf3(-/-)Il6(-/-) mice were highly susceptible to these infections. Moreover, in a model of SAIS, secondary infections caused considerably less mortality in Atf3(-/-) mice than in wild-type mice, indicating that ROS-induced ATF3 crucially determines susceptibility to secondary infections during SAIS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179317      PMCID: PMC3555699          DOI: 10.1038/nm.2557

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  54 in total

1.  Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection.

Authors:  Jose C Alves-Filho; Fabiane Sônego; Fabricio O Souto; Andressa Freitas; Waldiceu A Verri; Maria Auxiliadora-Martins; Anibal Basile-Filho; Andrew N McKenzie; Damo Xu; Fernando Q Cunha; Foo Y Liew
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

2.  Immunotherapy for sepsis--a new approach against an ancient foe.

Authors:  Richard S Hotchkiss; Steven Opal
Journal:  N Engl J Med       Date:  2010-07-01       Impact factor: 91.245

3.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.

Authors:  R C Bone; C J Fisher; T P Clemmer; G J Slotman; C A Metz; R A Balk
Journal:  N Engl J Med       Date:  1987-09-10       Impact factor: 91.245

4.  Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options.

Authors:  C A Gogos; E Drosou; H P Bassaris; A Skoutelis
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

Review 5.  Linking oxidative stress to inflammation: Toll-like receptors.

Authors:  Roop Gill; Allan Tsung; Timothy Billiar
Journal:  Free Radic Biol Med       Date:  2010-01-18       Impact factor: 7.376

6.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

7.  Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors:  C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal:  Crit Care Med       Date:  1994-01       Impact factor: 7.598

8.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

Review 9.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine.

Authors:  R C Bone; R A Balk; F B Cerra; R P Dellinger; A M Fein; W A Knaus; R M Schein; W J Sibbald
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

10.  Defective inflammatory response in interleukin 6-deficient mice.

Authors:  E Fattori; M Cappelletti; P Costa; C Sellitto; L Cantoni; M Carelli; R Faggioni; G Fantuzzi; P Ghezzi; V Poli
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  72 in total

1.  Function of GRIM-19, a mitochondrial respiratory chain complex I protein, in innate immunity.

Authors:  Yong Chen; Hao Lu; Qian Liu; Guochang Huang; Cheh Peng Lim; Lianhui Zhang; Aijun Hao; Xinmin Cao
Journal:  J Biol Chem       Date:  2012-06-04       Impact factor: 5.157

Review 2.  Are reactive oxygen species always detrimental to pathogens?

Authors:  Claudia N Paiva; Marcelo T Bozza
Journal:  Antioxid Redox Signal       Date:  2013-10-26       Impact factor: 8.401

3.  Endoplasmic reticulum stress-dependent activation of ATF3 mediates the late phase of ischemic preconditioning.

Authors:  Alan C Brooks; Yiru Guo; Mahavir Singh; James McCracken; Yu-Ting Xuan; Sanjay Srivastava; Roberto Bolli; Aruni Bhatnagar
Journal:  J Mol Cell Cardiol       Date:  2014-08-23       Impact factor: 5.000

Review 4.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

Review 5.  Immunopathogenesis of abdominal sepsis.

Authors:  Georg F Weber; Filip K Swirski
Journal:  Langenbecks Arch Surg       Date:  2014-01       Impact factor: 3.445

6.  Activating transcription factor 3-mediated chemo-intervention with cancer chemokines in a noncanonical pathway under endoplasmic reticulum stress.

Authors:  Seong-Hwan Park; Juil Kim; Kee Hun Do; Jiyeon Park; Chang Gyu Oh; Hye Jin Choi; Bo Gyoung Song; Seung Joon Lee; Yong Sik Kim; Yuseok Moon
Journal:  J Biol Chem       Date:  2014-08-13       Impact factor: 5.157

7.  The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A.

Authors:  Piotr J Dziunycz; Karine Lefort; Xunwei Wu; Sandra N Freiberger; Johannes Neu; Nadia Djerbi; Guergana Iotzowa-Weiss; Lars E French; Gian-Paolo Dotto; Günther F L Hofbauer
Journal:  J Invest Dermatol       Date:  2014-02-07       Impact factor: 8.551

8.  Activated Transcription Factor 3 in Association with Histone Deacetylase 6 Negatively Regulates MicroRNA 199a2 Transcription by Chromatin Remodeling and Reduces Endothelin-1 Expression.

Authors:  Chen Li; Yu Zhou; Anastacia Loberg; Stanley M Tahara; Punam Malik; Vijay K Kalra
Journal:  Mol Cell Biol       Date:  2016-10-28       Impact factor: 4.272

9.  Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.

Authors:  Joseph A Caruso; Rody Campana; Caimiao Wei; Chun-Hui Su; Amanda M Hanks; William G Bornmann; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells.

Authors:  Emmanuella Guenova; Yuliya Skabytska; Wolfram Hoetzenecker; Günther Weindl; Karin Sauer; Manuela Tham; Kyu-Won Kim; Ji-Hyeon Park; Ji Hae Seo; Desislava Ignatova; Antonio Cozzio; Mitchell P Levesque; Thomas Volz; Martin Köberle; Susanne Kaesler; Peter Thomas; Reinhard Mailhammer; Kamran Ghoreschi; Knut Schäkel; Boyko Amarov; Martin Eichner; Martin Schaller; Rachael A Clark; Martin Röcken; Tilo Biedermann
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.